Group 1 - The core business of the company is the construction, research and development, and service innovation of healthcare information technology [2] - The company offers a wide range of products including hospital information application software, public health information application software, and various cloud platforms [2] - The company has received multiple honors, including being recognized as a "China Software Integrity Demonstration Enterprise" and a "Top 100 Digital Economy Enterprise in Hangzhou" [2] Group 2 - In the latest financial report for 2024, the company achieved a revenue of 1.423 billion yuan, a year-on-year decrease of 11.96% [3] - The net profit for the same period was -173.52 million yuan, reflecting a year-on-year decline of 572.96% [3] - The company's gross profit margin stands at 45.18% [3] Group 3 - As of March 31, 2025, the number of shareholders increased to 82,383, with an average holding value of 352,800 yuan per shareholder [1] - The company's latest closing price was 5.28 yuan, down 1.31%, with a market-to-book ratio of 1.85 and a total market capitalization of 8.179 billion yuan [1][4] - The company's price-to-earnings ratio (TTM) is -47.14, compared to the industry average of 136.11 [4]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 6.75 [6][7]. Core Views - The company reported a revenue of RMB 1.423 billion for 2024, a year-on-year decline of 11.96%, and a net profit attributable to shareholders of -RMB 173.52 million, compared to a profit of RMB 36.69 million in the same period last year. This aligns with the company's previous performance forecast [1]. - The decline in revenue is attributed to systematic delays in project bidding and implementation by downstream clients, along with the ongoing market expansion of the new HI-HIS system [1]. - The company expects a reduction in goodwill impairment pressure in 2025, which may lead to a recovery in profitability [1]. Summary by Sections Financial Performance - The company's gross margin for 2024 was 45.18%, a decrease of 1.8 percentage points year-on-year. Revenue from technical services was RMB 567 million, down 6.54%, with a gross margin of 54.92%, up 0.90 percentage points. Software sales revenue was RMB 563 million, down 17.63%, with a gross margin of 51.81%, down 4.89 percentage points [2]. - The increase in sales, management, and R&D expense ratios was due to the new product's investment phase [2]. Order Growth and Product Promotion - In 2024, the company secured 31 software orders worth over RMB 10 million each in the smart hospital and public health markets, totaling RMB 580 million, compared to RMB 500 million in the previous year. The number of new HI-HIS system orders increased by 41% year-on-year [3]. - The company has completed several benchmark projects in regions such as South China, Central China, and Northwest China, enhancing its implementation efficiency and profitability potential for the HI-HIS product in 2025 [3]. AI and Product Competitiveness - The company has established strategic partnerships with over 300 medical institutions in the big data application field, integrating AI technology deeply into medical scenarios. The MedCopilot smart medical assistant is being promoted in conjunction with the HI-HIS system [4]. - This AI integration is expected to enhance the value of the company's medical information products and strengthen its competitive advantage [4]. Profit Forecast and Valuation - The company forecasts revenues of RMB 1.607 billion, RMB 1.821 billion, and RMB 2.071 billion for 2025, 2026, and 2027, respectively. The target price is set at 6.75 RMB, corresponding to a 6.5 times price-to-sales ratio for 2025 [5]. - The expected net profit attributable to shareholders for 2025 is RMB 133.28 million, with a significant recovery projected after the losses in 2024 [5].

Core Viewpoint - The company reported a decline in revenue and a net loss for 2024, primarily due to project delays and the initial phase of new product market expansion, but expects a recovery in profitability by 2025 [1][5]. Financial Performance - The company achieved a revenue of 1.423 billion yuan in 2024, a year-on-year decrease of 11.96%, and a net loss attributable to shareholders of 174 million yuan, compared to a profit of 37 million yuan in the same period of 2023 [1]. - In Q4 2024, revenue was 254 million yuan, down 44.65% year-on-year, with a net loss of 226 million yuan, compared to a loss of 55 million yuan in Q4 2023 [1]. - The overall gross margin for 2024 was 45.18%, a decrease of 1.8 percentage points year-on-year [2]. Revenue Breakdown - Technical service revenue was 567 million yuan, down 6.54% year-on-year, with a gross margin of 54.92%, up 0.90 percentage points [2]. - Software sales revenue was 563 million yuan, down 17.63% year-on-year, with a gross margin of 51.81%, down 4.89 percentage points [2]. Order Growth and Product Development - The company secured 31 software orders worth over 10 million yuan each in 2024, totaling 580 million yuan, compared to 29 orders worth 500 million yuan in 2023 [3]. - The number of new HI-HIS system orders increased to 31, a 41% year-on-year growth from 22 orders in 2023 [3]. - The company completed multiple benchmark projects in various regions, enhancing its implementation capabilities [3]. AI and Product Strategy - The company has established strategic partnerships with over 300 medical institutions in the big data application field, integrating AI technology into medical scenarios [4]. - The AI model "Qizhen Medical Model" is being applied in several core diagnosis and treatment processes, enhancing the company's competitive edge [4]. Future Projections - Revenue forecasts for 2025-2027 are 1.607 billion yuan, 1.821 billion yuan, and 2.071 billion yuan, respectively, reflecting a downward revision due to budget constraints [5]. - The company is assigned a target price of 6.75 yuan based on a 6.5x price-to-sales ratio for 2025, considering the accelerated promotion of the HI-HIS product [5].

Summary of the Conference Call for Chuangyue Huikang Company Overview - **Company**: Chuangyue Huikang - **Year**: 2024 - **Revenue**: 1.422 billion CNY - **Net Profit**: -192 million CNY - **Industry Contribution**: Medical industry accounted for 93.25% of revenue Key Financial Insights - Revenue decreased by 11.96% year-on-year, with a significant drop in net profit from 1.73 billion CNY to -192 million CNY [4][2] - Medical revenue from Corcept declined from 844 million CNY to 675 million CNY [4][2] - Public health sector orders dropped from 40% to approximately 30% of total orders due to insufficient fiscal funding [4][2] - Increased bad debt provisions by 70-80 million CNY negatively impacted net profit [4][2] Product and Project Developments - HIS system project contracts increased by 41% year-on-year, totaling 31 contracts [5][2] - Transition between old and new products extended delivery cycles, affecting product acceptance and payment timelines [5][2] - Plans to enhance the promotion of HealthFace products, with expectations for improved delivery cycles by the second half of the year [5][6] Collaborations and Partnerships - Collaboration with Philips is progressing well, although the promotion of Feiyuekang products did not meet expectations [7][2] - Future products will integrate into HealthSpace for easier client promotion [7][2] AI and Technology Advancements - Launched CDSS and other AI products, with over 20 clients in pilot programs and ten medical institutions completing applications post-Spring Festival [8][9] - Significant demand for AI solutions in the medical sector, with over ten hospitals having clear project implementations [10][2] - Collaboration with Zhejiang University to develop a medical large model, focusing on vertical industry knowledge integration and AR capabilities [11][2] Market Trends and Demand - Increased demand for AI in medical institutions, particularly for system upgrades and improvements [3][19] - Hospitals are preparing for new standards requiring AI functionalities, impacting existing module improvements [20][21] - The need for AI in hospitals is expected to influence project profit margins due to budget constraints [24][2] Future Directions - Plans to deepen AI integration into medical information systems over the next 5 to 10 years, focusing on algorithm development and data platform construction [14][2] - Emphasis on AR technology as a core component of medical processes rather than an auxiliary system [15][2] - Continued focus on enhancing diagnostic accuracy in grassroots medical settings through AI [28][2] Challenges and Strategic Responses - High costs associated with AI R&D and talent acquisition pose challenges, but partnerships with universities help mitigate these costs [22][2] - The company is adapting to budget constraints in hospitals, which may limit AI project funding [35][2] - The competitive landscape is shifting, with larger firms gaining market share while smaller companies struggle to survive [46][2] Conclusion Chuangyue Huikang is navigating a challenging financial landscape while making strides in AI and technology integration within the medical sector. The company is focusing on strategic partnerships, product development, and adapting to market demands to enhance its competitive position in the evolving healthcare landscape.

Group 1 - The core viewpoint is that the medical information industry is facing both challenges and opportunities in 2024, particularly for the company Chuangyue Huikang, which primarily serves public medical institutions and health management organizations [1] - Chuangyue Huikang's revenue has declined due to the long procurement cycles and uneven distribution of payment and project acceptance caused by the government fiscal budget system [1] - The company is advancing its "Huikang Cloud" strategy, focusing on cloud computing, intelligence, and ecosystem development, with successful bids in several large projects [1] Group 2 - In 2024, the company plans to launch the smart medical assistant MedCopilot, developed in collaboration with Zhejiang University, to create provincial-level grassroots smart medical solutions [1] - For 2025, the company aims to deepen the Huikang Cloud strategy, enhance system stability, optimize implementation processes, and innovate market expansion models [1] - The company is collaborating with HW and iFlytek to achieve technological synergies and promote intelligent upgrades [1]

Group 1 - The core viewpoint of the news is the disclosure of the annual report for 2024 by Chuangye Huikang (300451.SZ), highlighting the institutional investor holdings and changes in share ownership [1] - As of April 14, 2025, a total of 116 institutional investors disclosed holdings in Chuangye Huikang A-shares, with a total holding of 312 million shares, accounting for 20.16% of the total share capital [1] - The top ten institutional investors collectively hold 17.92% of the shares, with a decrease of 1.71 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, seven public funds reported a decrease in holdings compared to the previous quarter, with a reduction rate of 0.49% [2] - A total of 102 new public funds were disclosed this period, including notable funds such as Fuqua Stable Growth Mixed A and Huaxia CSI 1000 ETF [2] - One pension fund, the Basic Pension Insurance Fund 1205 Combination, reported a slight decrease in holdings compared to the previous quarter [2]

Financial Performance - In 2024, the company achieved a revenue of 1.423 billion CNY, a decrease of 11.96% compared to 2023 [2] - The net profit attributable to shareholders was -173 million CNY, marking the first annual loss since the company's IPO [2] Market and Product Development - The company added 31 new software projects worth 580 million CNY during the reporting period [3] - The number of new HI-HIS orders increased by 41% year-on-year, with 70% of clients being tertiary hospitals [3] Strategic Collaborations - The company partnered with Philips to enhance the CareSync product, integrating various medical technology solutions [4] - A provincial-level integrated healthcare system was developed in Jiangxi, covering 11 cities and 100 counties, managing 19 million residents' electronic health records [9] AI and Technology Advancements - The company launched the MedCopilot smart medical assistant, integrating AI technology for clinical decision support [8] - The BsoftGPT platform successfully integrated with advanced AI models, enhancing the company's capabilities in medical AI applications [8] Future Outlook and Strategic Initiatives - The company aims to strengthen its core business competitiveness and improve project implementation efficiency [10] - Plans to enhance AI model architecture and develop a data-driven intelligent healthcare ecosystem are underway [9] - The company will focus on financial risk management and improve cash flow efficiency through dynamic monitoring of accounts receivable [11]

Core Viewpoint - The company reported a significant decline in performance for the fiscal year 2024, attributing the drop in revenue and net profit to various factors including project delays, increased costs, and extended payment terms from clients [1][4]. Group 1: Financial Performance - For the fiscal year 2024, the company achieved a revenue of 1.423 billion yuan, representing a year-on-year decrease of 11.96% [4]. - The net profit attributable to shareholders was -174 million yuan, marking a shift from profit to loss for the first time since the company went public in 2015 [4]. - The net profit excluding non-recurring gains and losses was -192 million yuan [4]. Group 2: Operational Challenges - The company faced systematic delays in project bidding and implementation from downstream clients, which contributed to the revenue contraction [1]. - The introduction of the new HI-HIS system is still in the market adaptation phase, further impacting revenue [1]. - Increased goodwill impairment, high fixed costs, and extended payment cycles due to client budget controls have put significant pressure on net profit [1]. Group 3: Strategic Initiatives - The company is advancing its "Huikang Cloud Strategy," focusing on integrating artificial intelligence with healthcare services to enhance digital transformation for clients [1]. - Structural reforms in the R&D system are being implemented to build a modular technology architecture and intelligent R&D system, aiming for systematic improvements in R&D efficiency [1]. - Recent collaborations with major tech companies like Alibaba, Tencent, and Huawei have been established to innovate in smart healthcare and AI applications [1]. Group 4: Market Activity - After January 2023, the company's stock price surged from a low of 3.91 yuan to a high of 7.44 yuan, reflecting an increase of over 90% [2]. - The chairman, Zhang Lvzhen, sold 6 million shares for 43.92 million yuan through block trading on March 12 [2]. - The largest shareholder, Ge Hang, has also reduced his stake from 14.28% to 13.57% by selling 15.44 million shares [2]. Group 5: Current Market Status - As of April 14, 2023, the company's stock price closed at 5.66 yuan per share, with a total market capitalization of 8.768 billion yuan [3].

Financial Performance - The company reported a basic earnings per share of -0.1100 yuan for 2024, a decrease of 650% compared to 0.0200 yuan in 2023 [1] - The net profit for 2024 was -1.74 billion yuan, a significant decline of 570.27% from 0.37 billion yuan in 2023 [1] - Operating revenue decreased by 11.94% to 14.23 billion yuan in 2024 from 16.16 billion yuan in 2023 [1] - The return on equity was -3.85% in 2024, down from 0.80% in 2023, reflecting a decline of 581.25% [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 49,026.46 million shares, accounting for 32.11% of the circulating shares, a decrease of 2,356.35 million shares from the previous period [1] - The largest shareholder, Ge Hang, holds 22,051.92 million shares, representing 14.44% of the total share capital, with no change in holdings [2] - Philips (China) Investment Co., Ltd. is the second-largest shareholder with 15,500.31 million shares, also unchanged [2] Dividend Distribution - The company has announced no distribution or transfer of shares for the current period [1]

证券代码：300451 证券简称：创业慧康 公告编号：2025-018 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开 第八届董事会第十四次会议与第八届监事会第十次会议，审议通过了《关于作废 部分已授予尚未归属限制性股票的议案》。现将有关事项说明如下： 一、激励计划已履行的相关审批程序 1、2022 年 12 月 14 日，公司召开第七届董事会第二十二次会议，会议审议 通过了《关于<创业慧康科技股份有限公司 2022 年限制性股票激励计划（草案）> 及其摘要的议案》《关于<创业慧康科技股份有限公司 2022 年限制性股票激励计 划实施考核管理办法>的议案》《关于提请股东大会授权董事会办理 2022 年限制 性股票激励计划相关事宜的议案》及《关于召开公司 2022 年第三次临时股东大 会的议案》等议案。公司独立董事就本激励计划相关议案发表了独立意见。 同日，公司召开第七届监事会第十六次会议，审议通过了《关于<创业慧康 科技股份有限公司 2022 年限制性股票激励计划（草案）>及其摘要的议案》《关 于<创业慧康科技股份有限公司 2022 年限制性股票激励计划实施考核管理办法> ...